Kailera Therapeutics Announces First Participants Randomized in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide (KAI-9531)

Ribupatide (KAI-9531) aims to address critical need for greater weight loss, especially for people living with a BMI of 35 kg/m2 or greater –– ...
News-Medical.Net on MSN

GLP-1 weight-loss drugs show early promise for treating addiction

By Tarun Sai Lomte From laboratory models to small human trials, a new review explores whether popular metabolic drugs could ...
Targeted Oncology

New OrigAMI-1 Data Signal Shift Beyond First-Gen EGFR Inhibitors in Metastatic CRC

In the evolving landscape of metastatic colorectal cancer, managing patients with RAS/BRAF wild-type tumors remains a ...
IFLScience

How Do GLP-1 Agonists Like Ozempic and Wegovy Work?

Stephen has degrees in science (Physics major) and arts (English Literature and the History and Philosophy of Science), as well as a Graduate Diploma in Science Communication. Stephen has degrees in ...
The Scientist

GLP-1 Drug Side Effects May Be Tackled with More Mechanistic Studies

Glucagon-like peptide-1 (GLP-1) agonists have transformed weight loss treatments. However, about half of the patients who take these drugs stop within a year because of unwanted side effects. 1,2 For ...